A number of well-known pharmaceutical companies sell assets.

On September 3rd, The company reported that it achieved operating income of RMB9.656 billion in January-June 2020, a decrease of 8.23% from a year earlier, and a net profit attributable to shareholders of listed companies of RMB392 million, an increase of 16.56% over the same period last year.
, according to publicly disclosed information, the company sold a 70 per cent stake in another controlling subsidiary, Sichuan People's Fu.
according to the statement of People's Fu Pharmaceuticals: on the one hand, one after another to divest non-core pharmaceutical assets, continue to optimize the business, capital structure, on the other hand, adhere to the focus of resources to develop established professional sub-areas to achieve business focus.
In addition, according to the 2020 half-yearly report recently disclosed by Tiansli, Tiansli will focus its superior resources on the pharmaceutical industry through the sale of assets in the distribution and distribution business sector under the company's pharmaceutical business model, continue to promote the coordinated development of modern Chinese medicine, biopharmaceuticals and chemicals, and build innovative pharmaceutical research and development clusters.
to meet the strategic development needs of listed companies, enhance the sustainable development capacity of listed companies and core competitiveness.
According to the contents of the announcement, six partnerships under Tiansli and its indirect control, Tianjin Shanxuan, Tianjin Zhixuan, Tianjin Ruisheng, Tianjin Ruixuan, Tianjin Yanxiang and Tianjin Yanlong, sold all their shares in Tiansi Marketing to Chongqing Pharmaceuticals, which constitutes a major asset reorganization of listed companies as stipulated by the CSRC.
"Slim" destocking in addition, The company's first-half operating income was RMB1,095 million, down 42.06 percent from RMB1.89 billion a year earlier, while the net profit attributable to shareholders of listed companies was RMB84.02 million, down 143.54 percent from a year earlier.
statistics, this is the sixth quarter of losses since the price hike.
in addition to a large number of inventory needs to be sold out, the gross margin of East A gum also fell sharply.
According to the company's semi-annual report, in the first half of this year, Dong'a gum donkey farming and related business losses, the first half of donkey breeding and sales of operating income of 186 million yuan, corresponding costs of 190 million yuan, gross margin of -2.46%.
addition, Dong A gum also issued a notice to announce "slimming down", will hold a 25% stake in China Resources Onde Biopharmaceutical Co., Ltd. transferred to China Resources Biopharmaceuticals.
the related transaction has little impact on the company's overall earnings, and is able to recover equity investment funds of RMB74.408425 million, increasing the company's cash flow.
" it is understood that this is the first transfer of shares in a subsidiary since the "go-to-stock" of Dong'a Gum.
's 2020 half-year report, released recently by Haizheng Pharmaceuticals, shows that the company achieved operating income of 5.318 billion yuan and realized net profit of 240 million yuan, up 357.31% YoY, mainly due to the year-on-year decline in operating expenses due to higher gross margin on sales of the company's preparation products and higher operating efficiency.
fact, as early as January 7 this year, Haizheng Pharmaceuticals announced that the company's five apartments located in The Grand Hyatt Building A in Taizhou City, a total of 1.82 million yuan.
addition, on December 10 last year, Haizheng Pharmaceuticals announced that it would take into account the impairment provisions of assets of 1.317 billion yuan, and correspondingly reduce this year's net profit.
the company's liquidity needs through the sale of assets to insulge funds, but also shows the urgency of the company's liquidity needs.
addition, Kangmei Pharmaceuticals announced on August 27 that the company achieved revenue of 2.517 billion yuan, down 69.05 percent year-on-year, and a net loss of 1.424 billion yuan, compared with a profit of 85.5 million yuan a year earlier.
, Kangmei Pharmaceuticals said that the reporting period of the company focused on the main business, adjust business strategy, affected by the outbreak, revenue decreased year-on-year.
announcement pointed out that, in order to further incarnate assets, focus on the main business, its wholly-owned subsidiary Kangmei Health Industry Investment Co., Ltd. intends to sell the two state-owned construction land use rights and their above-ground and underground buildings and/or construction projects located in the Haizhu District A district of Guangzhou City and the Internet Innovation Cluster (10)-2 block in Haizhu District, Guangzhou City.
, the entire pharmaceutical industry is facing enormous challenges as a result of the new crown outbreak.
pharmaceutical companies continue to suffer from a downturn, whether domestic or multinational pharmaceutical companies, many have chosen to divest their core businesses or sell assets because of performance issues.
in the post-epidemic era, it is a challenge and an opportunity for the pharmaceutical industry.
as long as pharmaceutical companies can adjust their strategies in a timely manner, firmly keep up with the pace of industry development, the future will certainly be in a better direction.
.